Search
for

    Sort by

    Research 331–360 of 1000+

    1. Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19 Dermatologic therapy · 2020
    2. <i>In‐silico</i> Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its <i>In‐vitro</i> Evaluation ˜The œFASEB journal · 2020
    3. 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index Journal of Investigative Dermatology · 2019
    4. JAK inhibitors for the treatment of alopecia areata 2019
    5. 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching 2019
    6. 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata 2019
    7. 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells Journal of Investigative Dermatology · 2019
    8. P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis 프로그램북(구 초록집) · 2019
    9. 1359 Hair growth is induced by blockade of macrophage-derived oncostatin M and downstream JAK-STAT5 signaling in hair follicle stem cells Journal of Investigative Dermatology · 2018
    10. Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Figshare · 2018
    11. IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA Asian journal of pharmaceutical and clinical research · 2017
    12. 865 Conditional ablation of JAK-STAT5 signaling induces anagen hair growth Journal of Investigative Dermatology · 2017
    13. Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo Current dermatology reports · 2017
    14. 692 Study of the impact of SKPs’ secreted factors and of a botanical extract derived from jasmine on keratinocytes growth and reconstructed human epidermis thickness Journal of Investigative Dermatology · 2016
    15. 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors 2016
    16. 700 Oncostatin M is upstream of JAK-STAT signaling during the murine hair cycle Journal of Investigative Dermatology · 2016
    17. Hair Growth Activity of Seeds and Fruit Pulp of Eugenia jambolana (Jamun) Pharmacy & pharmacology international journal · 2015
    18. Janus kinase (JAK) SciBX · 2014
    19. JAAD Grand Rounds quiz∗ Journal of The American Academy of Dermatology · 2010
    20. J. Cosmet. Sci., 59, 203-215 (May/June 2008) �Effects of permanent waving on changes of protein and physicomorphological properties in human head hair International Journal of Cosmetic Science · 2009
    21. This Week in JAMA JAMA · 2009
    22. Correction of the Cornrow Transplant and Other Common Problems in Surgical Hair Restoration by James E. Vogel, M.D. Plastic and Reconstructive Surgery · 2000
    23. Report of Japanese Meeting, Tokyo, June 27, 1998 Hair transplant forum international · 1998
    24. Guest Editor: James E. Vogel, MD, FACS Dermatologic Surgery · 1997
    25. Topical Delivery of Atraric Acid Derived from Stereocaulon japonicum with Enhanced Skin Permeation and Hair Regrowth Activity for Androgenic Alopecia Pharmaceutics · 2023
    26. JAM-A facilitates hair follicle regeneration in alopecia areata through functioning as ceRNA to protect VCAN expression in dermal papilla cells Precision Clinical Medicine · 2022
    27. Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia? International Journal of Dermatology · 2021
    28. JAAD – Prevalence of Female Pattern Hair Loss in a multiracial population (supplementary data) 2021
    29. Generalized Vitiligo Associated Autoimmune Diseases in Japanese Patients Their Families Allergology International · 2011 · 81 citations
    30. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B Journal of the American Academy of Dermatology · 2018 · 74 citations